Table 2.

Distribution of ARV regimens prior to the switch to BIC/FTC/TAF

ARV regimen	N (%)
2NRTIs + INSTI	42 (46.2%)
2NRTIs + PI/c or PI/r	26 (28.6%)
2NRTIs + PI/c or PI/r + INSTI	6 (6.6%)
2NRTIs + NNRTI	2 (2.2%)
NRTI + PI/r + INSTI	2 (2.2%)
NNRTI + PI/r	2 (2.2%)
NNRTI + PI/r + INSTI	2 (2.2%)
Other	7 (7.7%)

Missing: n=2; % are calculated from the total number of treatment-experienced patients, n=91.

Other included: CCR5 inhibitor + INSTI, CCR5 inhibitor + NRTI + PI/r, 2NRTIs + NNRTI + INSTI, NNRTI + INSTI, PI/r + 3 NRTIs.

CCR5 – C-C chemokine receptor type 5; BIC/FTC/TAF – bictegravir/emtricitabine/tenofovir alafenamide; INSTI – integrase strand transfer inhibitor; NRTI – nucleos(t)ide reverse transcriptase inhibitor; NNRTI – non-nucleoside reverse transcriptase inhibitor; PI – protease inhibitor; /c – pharmacologically boosted with cobicistat; /r – pharmacologically boosted with ritonavir.